Table 4 Toxicity of imatinib and sorafenib combination in CRPC
All evaluable patients for toxicity ( N =17) | Dose level 0 (13 patients) (imatinib 300 mg +sorafenib 400 mg) | Dose level 1 (4 patients) (imatinib 400 mg+sorafenib 400 mg) | ||||
|---|---|---|---|---|---|---|
Adverse events | Grades 1 or 2 | Grades 3 or 4 | Grades 1 or 2 | Grades 3 or 4 | Grades 1 or 2 | Grades 3 or 4 |
Nausea | 4 (23%) | 0 | 3 (50%) | 0 | 1 (25%) | 0 |
Vomiting | 4 (23%) | 0 | 4 (31%) | 0 | 0 | 0 |
Rash | 8 (47%) | 1 (6%) | 7 (54%) | 1 (7.6%) | 1 (25%) | 0 |
Hand/foot | 1 (6%) | 1 (6%) | 1 (7.6%) | 0 | 0 | 1 (16%) |
Diarrhoea | 3 (17%) | 1 (6%) | 1 (7.6%) | 1 (7.6%) | 2 (33%) | 0 |
Constipation | 1 (6%) | 0 | 1 (7.6%) | 0 | 0 | 0 |
Fatigue | 2 (12%) | 0 | 1 (7.6%) | 0 | 1 (7.6%) | 0 |
Dehydration | 2 (12%) | 1 (6%) | 2 (15%) | 1 (7.6%) | 0 | 0 |
Weakness | 2 (12%) | 2 (12%) | 2 (15%) | 2 (15%) | 0 | 0 |
LE oedema | 2 (12%) | 0 | 2 (15%) | 0 | 0 | 0 |
Weight loss | 0 | 1 (6%) | 0 | 0 | 0 | 1 (7.6%) |
Periorbital oedema | 1 (6%) | 0 | 1 (7.6%) | 0 | 0 | 0 |
↑Creatinine | 3 (18%) | 1 (6%) | 3 (21%) | 1 (7.6%) | 0 | 0 |
Hyperglycaemia | 2 (12%) | 0 | 2 (15%) | 0 | 0 | 0 |
Hypocalcemia | 3 (18%) | 2 (12%) | 3 (21%) | 2 (15%) | 0 | 0 |
Elevated LFTs | 2 (12%) | 0 | 2 (15%) | 0 | 0 | 0 |
Neutropenia | 0 | 2 (12%) | 0 | 0 | 0 | 2 (33%) |
Lymphopenia | 0 | 3 (18%) | 0 | 3 (21%) | 0 | 0 |
Hypoalbunemia | 5 (29%) | 0 | 5 (38%) | 0 | 0 | 0 |
Hyponateremia | 2 (12%) | 0 | 2 (15%) | 0 | 0 | 0 |
